{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:18:09Z","timestamp":1792840689066,"version":"4.5.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Otolaryngology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.amjoto.2017.01.018","type":"journal-article","created":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T07:17:52Z","timestamp":1484810272000},"page":"354-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Nasal septal perforation secondary to systemic bevacizumab"],"prefix":"10.1016","volume":"38","author":[{"given":"Mathew","family":"Geltzeiler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby O.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjoto.2017.01.018_bb0005","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","article-title":"Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies","volume":"28","author":"Shih","year":"2006","journal-title":"Clin Ther"},{"issue":"March","key":"10.1016\/j.amjoto.2017.01.018_bb0010","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/lary.21345","article-title":"Safety of intranasal bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis","volume":"121","author":"Chen","year":"2011","journal-title":"Laryngoscope"},{"key":"10.1016\/j.amjoto.2017.01.018_bb0015","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/sj.bjc.6605828","article-title":"Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients","volume":"103","author":"Mailliez","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.amjoto.2017.01.018_bb0020","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3109\/0284186X.2010.537692","article-title":"Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients","volume":"50","author":"Ramiscal","year":"2011","journal-title":"Acta Oncol"},{"issue":"11","key":"10.1016\/j.amjoto.2017.01.018_bb0025","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1517\/14740338.2014.960388","article-title":"An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab","volume":"13","author":"D'Amico","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"September","key":"10.1016\/j.amjoto.2017.01.018_bb0030","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1097\/MLG.0b013e31817c4296","article-title":"Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy","volume":"118","author":"Burkart","year":"2008","journal-title":"Laryngoscope"},{"key":"10.1016\/j.amjoto.2017.01.018_bb0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11912-012-0236-x","article-title":"Nasal septal perforation from bevacizumab: a discussion of outcomes, management, and pharmacovigilance","volume":"14","author":"Ramiscal","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.amjoto.2017.01.018_bb0040","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00228-014-1687-9","article-title":"Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups","volume":"70","author":"Qi","year":"2014","journal-title":"Eur J Clin Pharmacol"}],"container-title":["American Journal of Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070916306111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070916306111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:00:43Z","timestamp":1759294843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196070916306111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0196070916306111"],"URL":"https:\/\/doi.org\/10.1016\/j.amjoto.2017.01.018","relation":{},"ISSN":["0196-0709"],"issn-type":[{"value":"0196-0709","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nasal septal perforation secondary to systemic bevacizumab","name":"articletitle","label":"Article Title"},{"value":"American Journal of Otolaryngology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjoto.2017.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}